TILDRAKIZUMAB, A SELECTIVE IL-23P19 ANTIBODY, IN THE TREATMENT OF CHRONIC PLAQUE PSORIASIS: RESULTS FROM TWO RANDOMIZED, CONTROLLED, PHASE 3 TRIALS

被引：0
|
作者：
Sinclair, R. [1 ]
Reich, K. [2 ,3 ]
Papp, K. [4 ]
Blauvelt, A. [5 ]
Tyring, S. [6 ]
Thaci, D. [7 ]
Cichanowitz, N. [8 ]
Mehta, A. [8 ]
Li, Q. [8 ]
Liu, K. [8 ]
La Rosa, C. [8 ]
Green, S. [8 ]
Kimball, A. [9 ]
机构：
[1] Univ Melbourne, Melbourne, Vic, Australia
[2] Sciderm Res Inst, Hamburg, Germany
[3] Dermatologikum Hamburg, Hamburg, Germany
[4] Prob Med Res, Waterloo, ON, Canada
[5] Oregon Med Res Ctr, Tigard, OR USA
[6] Univ Texas, Austin, TX USA
[7] Univ Lubeck, Lubeck, Germany
[8] Merck & Co Inc, Kenilworth, NJ USA
[9] Harvard Med Sch, Boston, MA USA
来源：
INTERNATIONAL JOURNAL OF DERMATOLOGY | 2017年 / 56卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
0177
引用
收藏
页码：1238 / 1239
页数：2
相关论文
共 50 条
  • [31] Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: Results from three randomized placebo-controlled phase III trials: Part I
    Pariser, David M.
    Gordon, Kenneth B.
    Papp, Kim A.
    Leonardi, Craig L.
    Kwon, Paul
    Compton, Peter G.
    Rundle, Amy Chen
    Walicke, Patricia A.
    Lebwohl, Mark
    JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2005, 9 (06) : 303 - 312
  • [32] EFFICACY AND SAFETY OF RISANKIZUMAB, A SELECTIVE IL-23P19 INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS OVER 24 WEEKS: RESULTS FROM A PHASE 2 TRIAL
    Mease, P. J.
    Kellner, H.
    Morita, A.
    Kivitz, A. J.
    Papp, K. A.
    Aslanyan, S.
    Berner, B.
    Chen, S.
    Eldred, A.
    Behrens, F.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 200 - 201
  • [33] Efficacy and safety of risankizumab, a selective IL-23p19 inhibitor, in patients with active psoriatic arthritis over 24 weeks: results from a phase 2 trial
    Mease, P. J.
    Kellner, H.
    Morita, A.
    Kivitz, A. J.
    Papp, K. A.
    Aslanyan, S.
    Berner, B.
    Chen, S.
    Eldred, A.
    Behrens, F.
    EXPERIMENTAL DERMATOLOGY, 2018, 27 : 9 - 9
  • [34] Safety and Efficacy of a Once-Daily Halobetasol Propionate 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Results of Two Phase 3 Randomized Controlled Trials
    Green, Lawrence J.
    Kerdel, Francisco A.
    Cook-Bolden, Fran E.
    Bagel, Jerry
    Lin, Tina
    Martin, Gina
    Pillai, Radhakrishnan
    Israel, Robert
    Ramakrishna, Tage
    JOURNAL OF DRUGS IN DERMATOLOGY, 2018, 17 (10) : 1062 - 1069
  • [35] Effect of Guselkumab (TREMFYA®), a Selective IL-23p19 Inhibitor, on Axial-Related Endpoints in Patients with Active PsA: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Through 2 Years
    Mease, Philip
    Helliwell, Philip S.
    Gladman, Dafna
    Poddubnyy, Denis
    Baraliakos, Xenofon
    Chakravarty, Soumya
    Kollmeier, Alexa
    Xu, Xie
    Sheng, Shihong
    Xu, Stephen
    Shawi, May
    van der Heijde, Desiree
    Deodhar, Atul
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 2760 - 2763
  • [36] Incidence of cardiovascular events in patients with moderate-to-severe plaque psoriasis treated with tildrakizumab: pooled analysis from a phase 2 and two phase 3 trials
    Bissonnette, R.
    Fernandez-Penas, P.
    Puig, L.
    Peserico, A.
    Fumero, E.
    Mendelsohn, A.
    Rozzo, S.
    Menter, A.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 46 - 47
  • [37] Safety and Efficacy Results from the Open Label Extension of a Phase 2 Trial of Risankizumab, a Selective IL-23p19 Inhibitor in Patients with Active Psoriatic Arthritis
    Papp, Kim
    Gooderham, Melinda
    Morita, Akimichi
    Kivitz, Alan
    Sinvhal, Ranjeeta
    Topp, Andrew
    Heap, Graham
    Eldred, Ann
    Mease, Philip
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [38] Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials
    Gold, Linda Stein
    Lebwohl, Mark G.
    Sugarman, Jeffrey L.
    Pariser, David M.
    Lin, Tina
    Martin, Gina
    Pillai, Radhakrishnan
    Israel, Robert
    Ramakrishna, Tage
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (02) : 287 - 293
  • [39] Efficacy of Tofacitinib for the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis in Patient Subgroups from Two Randomised Phase 3 Trials
    Menter, M. Alan
    Papp, Kim A.
    Cather, Jennifer
    Leonardi, Craig
    Pariser, David M.
    Krueger, James G.
    Wohlrab, Johannes
    Amaya-Guerra, Mario
    Kaszuba, Andrzej
    Nadashkevich, Oleg
    Tsai, Tsen-Fang
    Gupta, Pankaj
    Tan, Huaming
    Valdez, Hernan
    Mallbris, Lotus
    Tatulych, Svitlana
    JOURNAL OF DRUGS IN DERMATOLOGY, 2016, 15 (05) : 568 - 580
  • [40] Tapinarof cream for the treatment of plaque psoriasis: Efficacy and safety results from 2 Japanese phase 3 trials
    Igarashi, Atsuyuki
    Tsuji, Gaku
    Fukasawa, Shuichi
    Murata, Ryusei
    Yamane, Satoshi
    JOURNAL OF DERMATOLOGY, 2024, 51 (10): : 1269 - 1278
12345